JP2024518438A5 - - Google Patents

Info

Publication number
JP2024518438A5
JP2024518438A5 JP2023568528A JP2023568528A JP2024518438A5 JP 2024518438 A5 JP2024518438 A5 JP 2024518438A5 JP 2023568528 A JP2023568528 A JP 2023568528A JP 2023568528 A JP2023568528 A JP 2023568528A JP 2024518438 A5 JP2024518438 A5 JP 2024518438A5
Authority
JP
Japan
Application number
JP2023568528A
Other languages
Japanese (ja)
Other versions
JP2024518438A (ja
JPWO2022236136A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/028193 external-priority patent/WO2022236136A1/en
Publication of JP2024518438A publication Critical patent/JP2024518438A/ja
Publication of JP2024518438A5 publication Critical patent/JP2024518438A5/ja
Publication of JPWO2022236136A5 publication Critical patent/JPWO2022236136A5/ja
Pending legal-status Critical Current

Links

JP2023568528A 2021-05-07 2022-05-06 エキサテカン誘導体およびその抗体薬物複合体 Pending JP2024518438A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163185736P 2021-05-07 2021-05-07
US63/185,736 2021-05-07
US202163248705P 2021-09-27 2021-09-27
US63/248,705 2021-09-27
US202263321187P 2022-03-18 2022-03-18
US63/321,187 2022-03-18
PCT/US2022/028193 WO2022236136A1 (en) 2021-05-07 2022-05-06 Exatecan derivatives and antibody-drug conjugates thereof

Publications (3)

Publication Number Publication Date
JP2024518438A JP2024518438A (ja) 2024-05-01
JP2024518438A5 true JP2024518438A5 (https=) 2025-05-14
JPWO2022236136A5 JPWO2022236136A5 (https=) 2025-05-14

Family

ID=81851425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568528A Pending JP2024518438A (ja) 2021-05-07 2022-05-06 エキサテカン誘導体およびその抗体薬物複合体

Country Status (15)

Country Link
US (1) US20250101032A1 (https=)
EP (1) EP4334322A1 (https=)
JP (1) JP2024518438A (https=)
KR (1) KR20240036506A (https=)
AU (1) AU2022269073A1 (https=)
BR (1) BR112023023276A2 (https=)
CA (1) CA3219236A1 (https=)
CL (1) CL2023003304A1 (https=)
CO (1) CO2023016939A2 (https=)
GE (1) GEAP202416409A (https=)
IL (1) IL308246A (https=)
MX (1) MX2023013118A (https=)
PE (1) PE20241299A1 (https=)
TW (1) TW202309042A (https=)
WO (1) WO2022236136A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240038138A (ko) 2020-07-13 2024-03-22 리제너론 파마슈티칼스 인코포레이티드 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도
MX2023003778A (es) 2020-09-30 2023-04-26 Duality Biologics Suzhou Co Ltd Compuesto antitumoral, metodo de preparacion y uso del mismo.
CN114805377A (zh) * 2021-01-29 2022-07-29 明慧医药(杭州)有限公司 适用于抗体-药物偶联物的毒素分子
AU2022375634A1 (en) 2021-10-25 2024-06-06 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
EP4434548A1 (en) 2021-11-15 2024-09-25 Systimmune, Inc. Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof
US11814394B2 (en) 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
CA3241734A1 (en) * 2022-01-12 2023-07-20 Amy Han Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
EP4489790A1 (en) * 2022-03-10 2025-01-15 Vivasor, Inc. Antibody-drug conjugates and uses thereof
CN118696048A (zh) * 2022-05-09 2024-09-24 同宜医药(苏州)有限公司 一种喜树碱衍生物,基于其的抗体-药物偶联物和药物组合物,及其应用
KR20250075560A (ko) 2022-07-15 2025-05-28 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. 항-trop2 항체 및 이의 접합체
KR20250049293A (ko) * 2022-07-27 2025-04-11 밍훼이 파마슈티컬 (항저우) 리미티드 항체-약물 접합체 및 이의 용도
CN117510515A (zh) * 2022-07-28 2024-02-06 明慧医药(杭州)有限公司 适用于抗体-药物偶联物的毒素分子
CN117024438A (zh) * 2022-07-29 2023-11-10 杭州爱科瑞思生物医药有限公司 依沙替康衍生物及其应用
JP2025511436A (ja) * 2022-09-02 2025-04-16 メルク・シャープ・アンド・ドーム・エルエルシー エキサテカン由来トポイソメラーゼ-1阻害薬医薬組成物及びその使用
EP4594327A1 (en) 2022-09-30 2025-08-06 BeiGene Switzerland GmbH Ligand-drug conjugate of exatecan analogue, and medical use thereof
PE20252282A1 (es) * 2022-10-09 2025-09-18 Lanova Medicines Ltd Compuestos, composiciones y metodos
IL320634A (en) * 2022-11-04 2025-07-01 Alx Oncology Inc EXATECAN derivatives and antibody-drug conjugates
CN119855820A (zh) * 2022-12-16 2025-04-18 上海齐鲁制药研究中心有限公司 喜树碱类化合物及其制备方法和用途
WO2024130161A2 (en) 2022-12-16 2024-06-20 Bionecure Therapeutics Inc Novel camptothecin derivatives and conjugates thereof
IL321193A (en) * 2022-12-28 2025-07-01 Adcendo Aps Antibody-drug conjugates targeting UPARAP including extacan derivatives
CN119630672B (zh) * 2023-02-23 2026-01-30 一线医药(杭州)有限公司 喜树碱衍生物及其偶联物以及其制备方法和医药用途
CN116063311B (zh) * 2023-03-01 2025-09-26 金麦安博生物制药(苏州)有限公司 一种依喜替康衍生物及其制备方法
CN120916790A (zh) * 2023-03-27 2025-11-07 台湾浩鼎生技股份有限公司 Trop2耦合生物分子、医药组合物及方法
TW202438069A (zh) * 2023-03-30 2024-10-01 大陸商上海齊魯製藥研究中心有限公司 依喜替康衍生物及其抗體藥物偶聯物
EP4687996A1 (en) * 2023-04-05 2026-02-11 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
EP4687997A2 (en) * 2023-04-05 2026-02-11 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
EP4687995A1 (en) * 2023-04-05 2026-02-11 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
US20240398794A1 (en) 2023-04-07 2024-12-05 Terns Pharmaceuticals, Inc. COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF
WO2024227432A1 (zh) * 2023-04-30 2024-11-07 泰诚思(上海)生物医药有限公司 喜树碱衍生物、其制备方法及用途、抗体药物偶联物及其应用
CN119080792A (zh) * 2023-09-15 2024-12-06 杭州爱科瑞思生物医药有限公司 依沙替康羟胺衍生物及其应用
CN120641100A (zh) * 2023-09-22 2025-09-12 台湾浩鼎生技股份有限公司 用于抗体耦合的改良型连接符-负载物、医药组合物、及其应用
CN117417347A (zh) * 2023-09-28 2024-01-19 杭州爱科瑞思生物医药有限公司 卤素取代的依沙替康的酰胺衍生物及其制备方法和应用
CN117645608A (zh) * 2023-11-30 2024-03-05 昆山新蕴达生物科技有限公司 抗体药物偶联物及其应用
WO2025141153A1 (en) * 2023-12-29 2025-07-03 Oncomatryx Biopharma, S.L. Endo180 targeted antibody-drug conjugates
CN117986269A (zh) * 2024-01-18 2024-05-07 苏州提领生物制药有限公司 喜树碱衍生物及其制备方法和应用
WO2025167722A1 (zh) * 2024-02-06 2025-08-14 四川科伦博泰生物医药股份有限公司 稠环化合物及其制备方法和应用
WO2025207828A1 (en) * 2024-03-26 2025-10-02 Fulgent Pharma Llc Nanocomposition comprising modified exatecan and use thereof
WO2025233501A1 (en) * 2024-05-10 2025-11-13 Astrazeneca Ab Conjugates comprising a topoisomerase i inhibitor
WO2025247302A1 (zh) * 2024-05-31 2025-12-04 杭州中美华东制药有限公司 一种喜树碱类化合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3466976T1 (sl) * 2014-01-31 2021-12-31 Daiichi Sankyo Company, Limited Anti-her2 konjugat protitelesa-zdravila
JP6612738B2 (ja) * 2014-04-10 2019-11-27 第一三共株式会社 抗her2抗体−薬物コンジュゲート
WO2020063676A1 (zh) * 2018-09-26 2020-04-02 江苏恒瑞医药股份有限公司 依喜替康类似物的配体-药物偶联物及其制备方法和应用
CN111620927B (zh) * 2019-05-20 2022-11-11 烟台迈百瑞国际生物医药股份有限公司 一种抗体药物偶联物中间体的一锅法制备工艺
CN111689980A (zh) * 2019-05-26 2020-09-22 四川百利药业有限责任公司 一种喜树碱药物及其抗体偶联物
CN112125915A (zh) * 2019-09-18 2020-12-25 四川百利药业有限责任公司 一种喜树碱衍生物及其偶联物
MX2023003778A (es) 2020-09-30 2023-04-26 Duality Biologics Suzhou Co Ltd Compuesto antitumoral, metodo de preparacion y uso del mismo.

Similar Documents

Publication Publication Date Title
JP2024518438A5 (https=)
CL2025003816A1 (es) Trituradora de rodillos y un método para operar la misma
BR102022025291A2 (https=)
CL2025003768A1 (es) Sistema y métodos de cribado estático
CL2025003553A1 (es) Autoinyector y métodos de uso relacionados.
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
CN307048801S (https=)
CN307045907S (https=)
BY13163U (https=)
CN307048342S (https=)
CN307045658S (https=)